Sutib 50MG Capsule, containing the active ingredient Sunitinib at a dosage of 50mg, is a targeted therapy medication primarily used in the treatment of certain types of cancer, including renal cell carcinoma and gastrointestinal stromal tumors. This oral capsule is designed to inhibit tumor growth by blocking specific proteins that promote cancer cell proliferation and angiogenesis, the process through which tumors develop their blood supply. Sutib is composed of Sunitinib malate, which is a potent inhibitor of multiple receptor tyrosine kinases, making it effective in disrupting the signaling pathways that cancer cells rely on for survival and growth. The medication is typically prescribed for patients who have not responded to other treatments, providing a crucial option in the management of advanced cancer. As a result, Sutib 50MG Capsule plays a significant role in improving patient outcomes and quality of life in oncology.

Sutib 25MG Capsule (7’s) is a medication that contains Sunitinib as its active ingredient, specifically formulated to target and inhibit tumor growth in various types of cancer. This oral capsule is primarily used in the treatment of advanced renal cell carcinoma (kidney cancer) and gastrointestinal stromal tumors (GISTs) that cannot be surgically removed or have metastasized. Sunitinib works by blocking specific proteins that promote cancer cell proliferation and angiogenesis, thereby reducing the tumor’s ability to grow and spread. Each capsule contains 25 mg of Sunitinib, and the formulation is designed for optimal absorption and efficacy. Patients taking Sutib can expect a comprehensive approach to managing their cancer, as it not only targets the tumor directly but also affects the surrounding blood vessels that supply nutrients to the cancer cells. This dual action makes Sutib a vital component in the oncological therapeutic arsenal.

Sutib 12.5MG Capsule (7’s) is a targeted therapy medication that contains Sunitinib as its active ingredient, specifically formulated to combat certain types of cancer. This drug is primarily used in the treatment of advanced renal cell carcinoma (kidney cancer) and gastrointestinal stromal tumors (GISTs) that cannot be surgically removed or have metastasized. Each capsule contains 12.5 mg of Sunitinib, which works by inhibiting specific proteins that promote tumor growth and blood vessel formation, thereby slowing down the progression of cancer. Sutib is available in a convenient capsule form, making it easy for patients to incorporate into their daily medication regimen. As a potent anti-cancer agent, Sutib is essential for patients seeking effective treatment options for their conditions, and it is crucial to follow medical advice regarding its use to maximize its benefits.